Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.

Background: In January 2015, US FDA approved secukinumab, a human interleukin-17A (IL-17A) antagonist, for the treatment of plaque psoriasis.

Objective: To provide unbiased drug information about the efficacy and safety of secukinumab for the treatment of moderate to severe plaque psoriasis by performing meta-analysis.

Methods: PubMed and EMBASE database searches were conducted.

Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection.

Background: Hepatitis C virus infection is a worldwide health problem and one of the leading causes of cirrhosis and hepatocellular carcinoma. Recently, sofosbuvir was introduced to the therapeutic arsenal against this virus, thereby paving the way for all-oral regimen. Aims of the review This study aimed to systematically analyze the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection.